Patents Examined by Carla Myers
  • Patent number: 9873916
    Abstract: This invention relates to a composition and a method for prediction of a response to Trastuzumab therapy in a breast cancer patient, and more specifically, a composition, a kit, a DNA chip, and a method for predicting a response to Trastuzumab therapy by using polynucleotides each comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 9, 11 to 19, and 21 to 23 in the Sequence Listing or a nucleotide sequence derived therefrom by substitution of u with t, mutants thereof, derivatives thereof, or fragments thereof comprising at least 16 continuous nucleotides, or a polynucleotide comprising a complementary sequence thereof, and using an increase or decrease in Her2 protein expression level as an indicator.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: January 23, 2018
    Assignees: TORAY INDUSTRIES, INC., KYOTO UNIVERSITY
    Inventors: Akira Myomoto, Satoko Kozono, Fumiaki Sato, Masakazu Toi, Takayuki Ueno, Zhipeng Wang, Gozoh Tsujimoto, Kazuharu Shimizu
  • Patent number: 9873913
    Abstract: Improved methods of assessing status of a solid tumor cancer in a subject involving detection of tumor-associated mutations in the subject's blood.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: January 23, 2018
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Barbara Klughammer, Peter Meldgaard, Boe Sorensen, Julie Tsai, Wei Wen, Lin Wu
  • Patent number: 9856536
    Abstract: Methods and kits for characterizing a subject having a steroid-dependent disease such as prostate cancer are described. A method of treating a steroid-dependent disease in a subject by obtaining a biological sample from the subject, determining if the HSD3B1(1245C) gene or 3?HSD1(367T) protein is expressed in the biological sample, and providing treatment other than or in addition to steroid ablation to the subject if the HSD3B1(1245C) gene or 3?HSD1(367T) protein is expressed is also described.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: January 2, 2018
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Nima Sharifi, Kai-Hsiung Chang
  • Patent number: 9835625
    Abstract: In one aspect, the invention is directed to a method of detecting Cowden syndrome (CS) or CS-like syndrome in an individual comprising detecting the presence of a mutated succinate dehydrogenase B (SDHB), mutated succinate dehydrogenase D (SDHD) or combination thereof in the individual, wherein detection of a mutated SDHB, SDHD or a combination thereof indicates that the individual is positive for CS or CS-like syndrome. In another aspect, the invention is directed to a method of determining whether an individual is at risk for developing Cowden syndrome (CS) or CS-like syndrome comprising detecting the presence of a mutated succinate dehydrogenase B (SDHB), mutated succinate dehydrogenase D (SDHD) or combination thereof in the individual, wherein detection of a mutated SDHB, SDHD or a combination thereof indicates that the individual is at risk for developing for CS or CS-like syndrome.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: December 5, 2017
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventor: Charis Eng
  • Patent number: 9822415
    Abstract: The invention relates to methods for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment as well as methods for providing personalized medicine to patients based on the sequence of several SNPs associated with the onset of EPS. The invention relates as well to kits for carrying out the diagnostic and predictive medicine methods.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: November 21, 2017
    Assignees: UNIVERSITAT DE BARCELONA, HOSPITAL CLINIC DE BARCELONA, INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER, CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED (CIBER)
    Inventors: Sergi Mas Herrero, Patricia Gassó Astorga, Cristina Malagelada Grau, Miquel Bernardo Arroyo, Amalia Lafuente Flo
  • Patent number: 9783807
    Abstract: A nucleic acid molecule utilizable for Salmonella detection is provided. The nucleic acid molecule which binds to Salmonella includes any of the following polynucleotides (a) to (d): (a) a polynucleotide composed of any of base sequences of SEQ ID NOs: 1 to 17; (b) a polynucleotide composed of a base sequence obtained by deletion, substitution, insertion, and/or addition of one or more bases in any of the base sequences in the polynucleotide (a) and is bound to Salmonella; (c) a polynucleotide composed of a base sequence having an identity of 80% or more to any of the base sequences in the polynucleotide (a) and is bound to Salmonella; and (d) a polynucleotide composed of a base sequence complementary to a polynucleotide which hybridizes to the polynucleotide (a) composed of any of the base sequences under stringent conditions and is bound to Salmonella.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: October 10, 2017
    Assignee: NEC SOLUTION INNOVATORS, LTD.
    Inventors: Hirotaka Minagawa, Jou Akitomi, Naoto Kaneko, Makio Furuichi, Katsunori Horii, Iwao Waga
  • Patent number: 9777329
    Abstract: The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: October 3, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stephen Quake, Hei-Mun Christina Fan
  • Patent number: 9765406
    Abstract: The oligonucleotide of sequence SEQ ID No.1: 5?-CTAGAGATCCCTCAGA-3?, and the complementary sequence thereof of sequence SEQ ID No.2: 5?-TCTGAGGGATCTCTAG-3? useful as probes to detect and quantify all HIV-1 circulating forms and their precursors SIVcpz/SIVgor.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: September 19, 2017
    Assignee: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD)
    Inventors: Martine Peeters, Lucie Etienne
  • Patent number: 9758830
    Abstract: A method for diagnosing and/or evaluating dementia severity in a subject suspected of having or having dementia is provided the method comprising: a) obtaining a test cell sample from the subject, b) assaying the test cell sample to determine a telomere organization signature of the test sample, the telomere organization signature comprising one or more parameters selected from: i) telomere aggregates; ii) telomere number; iii) telomere length and telomere number; iv) telomere aggregates, telomere length and telomere numbers; c) comparing the test cell sample telomere organization signature to a control or one or more predetermined reference signatures; and d) diagnosing whether the subject has dementia and/or the dementia severity according to the test sample telomere organization signature.
    Type: Grant
    Filed: September 20, 2014
    Date of Patent: September 12, 2017
    Assignee: 3D SIGNATURES INC.
    Inventors: Sabine Mai, Angeles Garcia
  • Patent number: 9727691
    Abstract: The present invention provides a method for evaluating (predicting, etc.) an individual difference (the tendency of every individual) in terms of drug sensitivity and disease vulnerability, comprising using a gene polymorphism of a cyclic AMP responsive element binding protein gene or the like. The method for evaluating drug sensitivity and the method for evaluating disease vulnerability according to the present invention comprise associating a gene polymorphism of a cyclic AMP responsive element binding protein gene or a haplotype constituted by the gene polymorphism with the drug sensitivity and disease vulnerability of an individual.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: August 8, 2017
    Inventors: Kazutaka Ikeda, Daisuke Nishizawa, Kenichi Fukuda
  • Patent number: 9719141
    Abstract: The invention provides methods and compositions for early diagnosis and treatment of a disease associated with a specific antibody by employing the detection of a cross-idiotypic epitope on the specific antibody to detect the cells that produce the antibody before the development of clinical symptoms of the disease.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: August 1, 2017
    Inventor: Vincent Agnello
  • Patent number: 9719140
    Abstract: Methods and materials for detection of aneuploidy and other chromosomal abnormalities using fetal tissue are disclosed. Results can be obtained rapidly, without cell culture. The method uses digital PCR for amplification and detection of single target sequences, allowing an accurate count of a specific chromosome or chromosomal region. Specific polynucleic acid primers and probes are disclosed for chromosomes 1, 13, 18, 21, X and Y. These polynucleic acid sequences are chosen to be essentially invariant between individuals, so the test is not dependent on sequence differences between fetus and mother.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: August 1, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Hei-Mun Christina Fan, Stephen R. Quake
  • Patent number: 9695480
    Abstract: The present application relates to an ex vivo or in vitro method to determine the presence or absence of a mutation or a variation in the NF-E2 gene in a sample from a patient suffering from a myeloid neoplasm or solid tumor whereby said method comprises: a) obtaining a nucleic acid sample from the patient, b) detecting the presence or absence of a mutation in the nucleic acid sample comprising the NF-E2 gene or a fragment thereof, characterized in that the presence of the mutation is an indication of a myeloid neoplasm or solid tumor, whereby the mutation is determined by comparing the nucleic acid sequence obtained from the sample with SEQ ID NO:1 or the complement thereof.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: July 4, 2017
    Assignee: Universitaetsklinikum Freiburg
    Inventors: Heike Pahl, Jonas Jutzi
  • Patent number: 9677139
    Abstract: The invention relates to the fields of therapeutics and identifying candidates for therapy, in particular to a method of identifying candidates for trastuzumab (Herceptin®) therapy in a patient presenting with breast cancer based on the presence or absence of specific genetic markers in a tumor sample from said patient.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: June 13, 2017
    Assignee: COLD SPRING HARBOR LABORATORY
    Inventors: James Hicks, Alexander Krasnitz
  • Patent number: 9677137
    Abstract: This document provides methods and materials involved in detecting translocations of TBL1XR1 and TP63 nucleic acid. For example, methods and materials for detecting TBL1XR1 and TP63 gene rearrangements (e.g., translocations) associated with cancer (e.g., T-cell lymphomas) as well as methods and materials for detecting cancers (e.g., T-cell lymphomas) with a dominant negative TP63 phenotype are provided.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: June 13, 2017
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: George Vasmatzis, Andrew L. Feldman, Sarah H. Johnson, Rhett P. Ketterling, Ryan A. Knudson, Kathryn E. Pearce, Julie C. Porcher
  • Patent number: 9670548
    Abstract: A method of identifying a subject with increased risk of colorectal cancer includes obtaining a biological sample from the subject, measuring the level of Fusobacterium nucleatum in the biological sample, and comparing the measured level to a control level, wherein an increased measured level compared to the control level is indicative of increased risk of colorectal cancer in the subject.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: June 6, 2017
    Assignee: Case Western Reserve University
    Inventor: Yiping Han
  • Patent number: 9670554
    Abstract: Oligomers useful for determining the presence of Trichomonas vaginalis in a test sample.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: June 6, 2017
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Barbara Susan Weinbaum, Janel M. Dockter, Astrid R. W. Schroder
  • Patent number: 9637797
    Abstract: Provided in the present invention are a method using in vitro measurement of the content of methylation or demethylation of GFRa1 CpG islands to estimate a risk of tumorigenesis and of tumor metastasis, or postoperative life expectancy, and a nucleotide sequence used.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: May 2, 2017
    Assignee: Beijing Institute For Cancer Research
    Inventors: Dajun Deng, Jun Zhang, Zhaojun Liu, Jing Zhou, Liankun Gu, Baozhen Zhang
  • Patent number: 9629839
    Abstract: Nucleic acids and proteins having a mutant C-RAF sequence, and methods of identifying patients having cancer who are likely to benefit from a combination therapy and methods of treatment are provided.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: April 25, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Caroline Emery, Rajee Antony, Levi A. Garraway
  • Patent number: 9624544
    Abstract: The present invention provides methods, kits, and compositions for detecting mutations in transient receptor potential cation channel, subfamily V, member 4 (TRPV4). In particular, mutations are detected in TRPV4 to detect diseases such as scapuloperoneal spinal muscular atrophy (SPSMA) and hereditary motor and sensory neuropathy type IIC (HMSN IIC) or Charcot-Marie-Tooth disease type 2C (CMT2C).
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: April 18, 2017
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Teepu Siddique, Han-Xiang Deng, Jianhua Yan